NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) posted its earnings results on Monday, February, 10th. The company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.16. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Friday, May 22nd 2020. View Earnings Estimates for Myovant Sciences.

7 Wall Street analysts have issued twelve-month price targets for Myovant Sciences' shares. Their forecasts range from $15.00 to $34.00. On average, they expect Myovant Sciences' share price to reach $24.20 in the next twelve months. This suggests a possible upside of 106.7% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

Media coverage about MYOV stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myovant Sciences earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Myovant Sciences.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE), Revance Therapeutics (RVNC), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Bellicum Pharmaceuticals (BLCM), Exelixis (EXEL), Fate Therapeutics (FATE) and Intercept Pharmaceuticals (ICPT).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (4.60%), Victory Capital Management Inc. (2.78%), Victory Capital Management Inc. (2.75%), Lord Abbett & CO. LLC (2.08%), FMR LLC (0.73%) and Platinum Investment Management Ltd. (0.30%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Victory Capital Management Inc., Bank of America Corp DE, Platinum Investment Management Ltd., Virginia Retirement Systems ET AL and Tower Research Capital LLC TRC . Company insiders that have sold Myovant Sciences company stock in the last year include Frank Karbe, Kim Sablich and Matthew Lang. View Insider Buying and Selling for Myovant Sciences.

MYOV stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Candriam Luxembourg S.C.A., Raymond James & Associates, Oxford Asset Management LLP, Parkman Healthcare Partners LLC and California Public Employees Retirement System. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $11.71.